about
Importance of Shank3 protein in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapsesAnimal models of myasthenia gravis: utility and limitationsMuscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological studyMyasthenia gravis (MG): epidemiological data and prognostic factors.Long-term cardiovascular autonomic and clinical changes after immunoglobulin G immunoadsorption therapy in autoimmune autonomic ganglionopathy.Risk factors for tumor occurrence in patients with myasthenia gravis.Variable disease severity in Saudi Arabian and Sudanese families with c.3924 + 2 T > C mutation of LAMA2.VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis.LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients.Immunotherapy responsive startle with antibodies to voltage gated potassium channels.Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats.Current and emerging therapies for the treatment of myasthenia gravis.Up-regulation of neural and cell cycle-related microRNAs in brain of amyotrophic lateral sclerosis mice at late disease stageIncreased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution.Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse.The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis.Autophagy, inflammation and innate immunity in inflammatory myopathiesClC-1 chloride channels: state-of-the-art research and future challenges.Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine.Comparison of Diffusion MRI Acquisition Protocols for the In Vivo Characterization of the Mouse Spinal Cord: Variability Analysis and Application to an Amyotrophic Lateral Sclerosis Model.The European LEMS Registry: Baseline Demographics and Treatment ApproachesClinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker studyThe natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates.Comparative neuronal differentiation of self-renewing neural progenitor cell lines obtained from human induced pluripotent stem cells.Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositisMarked phenotypic variability in two siblings with congenital myasthenic syndrome due to mutations in MUSK.Treatment of myasthenia gravis: focus on pyridostigmine.The thymus in myasthenia gravis: Site of "innate autoimmunity"?Recommendations for myasthenia gravis clinical trials.Autoimmune mechanisms in myasthenia gravis.Factors related to difficulties with employment in patients with multiple sclerosis: a review of 2002-2011 literature.Etiology of myasthenia gravis: innate immunity signature in pathological thymus.Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis.Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.Inflammation and epstein-barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis.A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis.Human CD14+ cells loaded with Paclitaxel inhibit in vitro cell proliferation of glioblastoma.Percutaneous vertebroplasty in a series of myasthenic patients with steroid-induced symptomatic vertebral fractures.Psychosocial difficulties of individuals with multiple sclerosis: the PARADISE-24 questionnaire.Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
P50
Q24317227-D9AD2E17-395A-475E-A5B4-6EAAA5F709E4Q26750632-BFAECAAC-55DD-414F-99C0-F7F4764DD32FQ28205102-20316307-C1B5-42DB-B4D6-8C6C655B7068Q30883242-0821BFB2-2139-43B6-86B3-06D69381B662Q33168432-BB36E61D-42AB-43E2-853B-50E435C20989Q33423900-60542A87-E864-41D8-8BBA-9A329ED2D201Q34100017-1A4AFB20-B5D4-44A4-B9A8-0A757059AF66Q34286801-D7E7EFAA-17DA-4AC7-8582-847AFCF4580CQ34418801-7498FA3C-4D4D-458B-86C3-3A00594F25DDQ34524200-D2A3280F-BABD-4830-9F10-5CF5FA7D56B0Q34746256-0DE0A69A-C427-4D42-98C5-58D2E2798D24Q34879129-1A9CEE57-B7DA-4796-830F-BFBC4C796197Q35052630-DBFB8898-D4E1-4D1F-A219-CF3C5BC0D9FDQ35084929-EA046C17-ECFA-4B27-A7FD-9FBCBB51DA5CQ35145764-01173662-5A23-4C1E-B9B9-4022276EA23BQ35230251-B873A4E9-6E7C-480F-B9E9-F7BBFB0989E4Q35388047-F02B6C88-16EB-4264-9F98-A015B43875ABQ35541006-701785FD-C300-4EF7-B46E-2BC935A6181BQ35753459-93043318-45B4-4B74-942F-C649624EC56CQ36112950-E26B1643-0FF5-4CF9-917B-9067248414F7Q36389693-7D7D5E38-8925-49E1-8F72-55F14DF1DD55Q36856405-40544138-8C9E-49F4-A6F8-79C7AE76C697Q36866151-75B55F76-4D74-4165-84A9-22BF322DE153Q37217420-87B580F5-C7C7-4039-B087-DCF94CD1EED1Q37371636-43D64A66-F241-4AB2-809D-901BDC01098BQ37699532-27CA257F-8B9C-46D7-9B96-BD5D61C3B04BQ37911501-12145474-6CCF-4AD4-9934-00E59DD99FD0Q37933171-046B5038-1676-40B8-8E0C-2FE6D786C0B5Q38009753-1D0DE872-6921-42EE-8942-CB8836FA2F56Q38039921-71946E4A-CD02-41A6-AA72-04490C55ACC8Q38067271-4C691C9B-0D8D-46C8-B3E9-D7AF5284E9C2Q38093708-7E21070C-3CF3-48A9-94D0-3C2A1FBB51D1Q38115565-753ADFBF-31FD-4099-9BD6-E429C54885D7Q38183705-B526D4E2-9797-4AF0-8BB9-FCE36FD6C3CEQ38562557-A3534687-559B-4043-BAFE-CBAB0CFCA26DQ38737653-FC3D0A42-1125-4C96-AAE0-31CC6716E967Q38933927-C94BC2E4-1E45-43EE-AC67-6BF8E7B5936EQ39229795-5D68C765-8E1C-407A-8810-8A193BBC8212Q39297158-A065858A-F021-4472-BBA2-48BA537C9EEEQ39368677-FD8E7EEC-1194-4609-AE79-96C274CC3F60
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Renato Mantegazza
@ast
Renato Mantegazza
@en
Renato Mantegazza
@es
Renato Mantegazza
@nl
Renato Mantegazza
@sl
type
label
Renato Mantegazza
@ast
Renato Mantegazza
@en
Renato Mantegazza
@es
Renato Mantegazza
@nl
Renato Mantegazza
@sl
prefLabel
Renato Mantegazza
@ast
Renato Mantegazza
@en
Renato Mantegazza
@es
Renato Mantegazza
@nl
Renato Mantegazza
@sl
P106
P1153
7007022015
P21
P31
P496
0000-0002-9810-5737